Pre-Made Naptumomab Estafenatox biosimilar, Fusion Protein, Naptumomab-Anti-TPBG Antibody: Anti-5T4/5T4AG/M6P1/WAIF1 therapeutic antibody fused with Staphylococcus aureus enterotoxin E SEA/E120 superantigen (synthetic) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Naptumomab Estafenatox biosimilar, Fusion Protein, Naptumomab-Anti-TPBG Antibody: Anti-5T4/5T4AG/M6P1/WAIF1 therapeutic antibody fused with Staphylococcus aureus enterotoxin E SEA/E120 superantigen (synthetic) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
| Products Name (INN Index) | Pre-Made Naptumomab Estafenatox biosimilar, Fusion Protein, Naptumomab-Anti-TPBG Antibody: Anti-5T4/5T4AG/M6P1/WAIF1 therapeutic antibody fused with Staphylococcus aureus enterotoxin E SEA/E120 super |
|---|---|
| INN Name | naptumomab estafenatox |
| Target | TPBG |
| Format | Fusion Protein |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | Fab – G1 – kappa |
| VD LC | Fab – G1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Active?Biotech?AB (Lund Sweden) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TPBG |
| Package |
